These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

861 related items for PubMed ID: 25180461

  • 1. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
    Markauskas A, Mogensen O, dePont Christensen R, Jensen PT.
    Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
    [Abstract] [Full Text] [Related]

  • 2. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL.
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [Abstract] [Full Text] [Related]

  • 3. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
    Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, Costantini B, Margariti PA, Gueli Alletti S, Cosentino F, Tortorella L, Scambia G.
    Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
    [Abstract] [Full Text] [Related]

  • 4. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
    Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta DM, Horowitz NS, del Carmen MG, Schorge JO.
    Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
    [Abstract] [Full Text] [Related]

  • 5. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B, Noventa M, Cvjeticanin B, Barbic M, Meglic L, Herzog M, Bordi G, Vitagliano A, Saccardi C, Skof E.
    Radiol Oncol; 2018 Sep 11; 52(3):307-319. PubMed ID: 30210049
    [Abstract] [Full Text] [Related]

  • 6. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
    Luo Y, Lee M, Kim HS, Chung HH, Song YS.
    Medicine (Baltimore); 2016 Sep 11; 95(36):e4797. PubMed ID: 27603388
    [Abstract] [Full Text] [Related]

  • 7. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C, Yao K, Li L, Yi T, Zhao X.
    Arch Gynecol Obstet; 2016 Jan 11; 293(1):163-168. PubMed ID: 26198168
    [Abstract] [Full Text] [Related]

  • 8. Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study.
    Gadducci A, Cosio S, Zizioli V, Notaro S, Tana R, Panattoni A, Sartori E.
    Int J Gynecol Cancer; 2017 Jan 11; 27(1):28-36. PubMed ID: 27870700
    [Abstract] [Full Text] [Related]

  • 9. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study.
    Fagö-Olsen CL, Ottesen B, Kehlet H, Antonsen SL, Christensen IJ, Markauskas A, Mosgaard BJ, Ottosen C, Soegaard CH, Soegaard-Andersen E, Hoegdall C.
    Gynecol Oncol; 2014 Feb 11; 132(2):292-8. PubMed ID: 24321400
    [Abstract] [Full Text] [Related]

  • 10. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y, Li Y, Cui H, Liang XD, Tang ZJ, Li XP, Zhao Y, Wei LH.
    Zhonghua Fu Chan Ke Za Zhi; 2012 May 11; 47(5):355-60. PubMed ID: 22883524
    [Abstract] [Full Text] [Related]

  • 11. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
    Wang DF, Zhang GN, Peng CR, Shi Y, Shi XW.
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jun 25; 56(6):385-392. PubMed ID: 34154313
    [Abstract] [Full Text] [Related]

  • 12. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Ghirardi V, Moruzzi MC, Bizzarri N, Vargiu V, D'Indinosante M, Garganese G, Pasciuto T, Loverro M, Scambia G, Fagotti A.
    Gynecol Oncol; 2020 Apr 25; 157(1):209-213. PubMed ID: 31952843
    [Abstract] [Full Text] [Related]

  • 13. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
    Angeles MA, Rychlik A, Cabarrou B, Spagnolo E, Guyon F, Pérez-Benavente A, Gil-Moreno A, Siegrist J, Querleu D, Mery E, Gladieff L, Hernández A, Ferron G, Martinez A.
    Gynecol Oncol; 2020 Sep 25; 158(3):614-621. PubMed ID: 32709536
    [Abstract] [Full Text] [Related]

  • 14. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
    Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR.
    Gynecol Oncol; 2012 Jan 25; 124(1):10-4. PubMed ID: 21917306
    [Abstract] [Full Text] [Related]

  • 15. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
    Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, del Carmen MG, Horowitz NS.
    Gynecol Oncol; 2013 Apr 25; 129(1):63-8. PubMed ID: 23337490
    [Abstract] [Full Text] [Related]

  • 16. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
    Coleridge SL, Bryant A, Kehoe S, Morrison J.
    Cochrane Database Syst Rev; 2021 Jul 30; 7(7):CD005343. PubMed ID: 34328210
    [Abstract] [Full Text] [Related]

  • 17. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
    Maheshwari A, Kumar N, Gupta S, Rekhi B, Shylasree TS, Dusane R, Bajpai J, Ghosh J, Gulia S, Deodhar K, Menon S, Popat P, Sable N, Thakur M, Kerkar R.
    Indian J Cancer; 2018 Jul 30; 55(1):50-54. PubMed ID: 30147093
    [Abstract] [Full Text] [Related]

  • 18. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
    Colombo PE, Labaki M, Fabbro M, Bertrand M, Mourregot A, Gutowski M, Saint-Aubert B, Quenet F, Rouanet P, Mollevi C.
    Gynecol Oncol; 2014 Nov 30; 135(2):223-30. PubMed ID: 25220627
    [Abstract] [Full Text] [Related]

  • 19. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.
    Vermeulen CKM, Tadesse W, Timmermans M, Kruitwagen RFPM, Walsh T.
    Eur J Obstet Gynecol Reprod Biol; 2017 Dec 30; 219():100-105. PubMed ID: 29078115
    [Abstract] [Full Text] [Related]

  • 20. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?
    Worley MJ, Guseh SH, Rauh-Hain JA, Williams KA, Muto MG, Feltmate CM, Berkowitz RS, Horowitz NS.
    Gynecol Oncol; 2013 Apr 30; 129(1):69-73. PubMed ID: 23375727
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.